Pfizer Inc. (NYSE:PFE) Shares Purchased by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,556,028 shares of the biopharmaceutical company’s stock after purchasing an additional 163,269 shares during the period. Asset Management One Co. Ltd.’s holdings in Pfizer were worth $64,770,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Sage Mountain Advisors LLC raised its position in Pfizer by 7.3% in the fourth quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 1,404 shares in the last quarter. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Acorn Financial Advisory Services Inc. ADV increased its holdings in shares of Pfizer by 32.8% in the 4th quarter. Acorn Financial Advisory Services Inc. ADV now owns 9,288 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 2,292 shares in the last quarter. Aptus Capital Advisors LLC lifted its stake in shares of Pfizer by 124.0% in the fourth quarter. Aptus Capital Advisors LLC now owns 223,203 shares of the biopharmaceutical company’s stock valued at $5,922,000 after purchasing an additional 123,543 shares during the period. Finally, Fisher Asset Management LLC boosted its holdings in Pfizer by 79.5% during the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock worth $295,760,000 after buying an additional 4,938,209 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PFE. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Cantor Fitzgerald began coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Finally, Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Price Performance

NYSE:PFE opened at $24.04 on Tuesday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm has a market cap of $136.68 billion, a price-to-earnings ratio of 17.42, a price-to-earnings-growth ratio of 0.87 and a beta of 0.57. The company’s 50-day moving average is $23.30 and its two-hundred day moving average is $24.88. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the business posted $0.82 earnings per share. The company’s revenue was down 7.8% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.15%. The ex-dividend date was Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.